
CGON$81.90▲ 2.4%CG Oncology's drug met its trial goal. Its first FDA application now runs into 2027
CG Oncology said Nov. 16 its bladder-cancer drug cut the risk of recurrence 68% in a Phase 3 trial. The same release set a later date to finish its first FDA application than its report 10 days earlier.
KeyVex News··5 min readFact-checked against 14 public records
KeyVex News··5 min readFact-checked against 14 public records
CGON$81.90▲ 2.4%Close, Nov. 19. Prices from Tiingo.The short versionTap to readTap to close
- A company can't sell a new drug until the FDA approves its application. CG Oncology began its first one in late 2025, and on Nov. 6 still expected to finish it in the fourth quarter.
- Instead, its Nov. 16 release moved completion to before the end of March 2027. The company said FDA feedback led it to add another group of bladder-cancer patients.
- That matters because the FDA's review clock does not start until a company says its application is complete, FDA guidance says. CG Oncology has no product sales yet.
- On Nov. 18, after the results and the new date were public, chief executive Arthur Kuan bought about $2.4 million of stock. His filings show no earlier open-market purchase.
- The company will present the full trial data on Dec. 2.
The result: CG Oncology said on Nov. 16, before the market opened, that its drug cretostimogene cut the risk of bladder cancer coming back by 68%. The comparison group got surveillance alone, with no added treatment. The Phase 3 trial, called PIVOT-006, enrolled 367 patients.8-K CG Oncology's stock closed up 14% at $84.78, its highest close since it listed in January 2024.Chart data
The date: Its quarterly report, filed Nov. 6, said the company expected to finish its first FDA application in the fourth quarter.10-Q On Nov. 16, chief executive Arthur Kuan said it now expects to finish "before the end of March 2027." He said FDA feedback led the company to add a group of patients to the application.8-K
Why it matters: CG Oncology has no product to sell, and the FDA does not start the clock on its review until an application is complete.10-QFDA March 2027 is the third completion target it has given since starting the application in the fourth quarter of 2025: first "in 2026," then the fourth quarter, now March. Only the latest falls outside 2026.10-Q8-K8-K8-K
The buy: On Nov. 18, two days after the results and the new date were made public, Kuan bought about $2.4 million of stock at $78.88 a share, according to his Form 4, the filing officers and directors make when their holdings change. It does not mark the purchase as part of a trading plan. His filings since the company listed show no earlier open-market purchase.Form 4EDGAR
CG Oncology's stock and the dates it setDaily close, Aug. 1, 2025 to Nov. 19, 2026 ▲ 211.3%Show chartHide chart
What the trial showed, and what the release left out
PIVOT-006 tested the drug in patients with intermediate-risk disease and small high-grade tumors, after surgery to remove the tumors. The comparison group got surveillance, not another drug. There is no FDA-approved treatment to give after surgery for this group, which the company puts at about 50,000 patients.8-K
Median follow-up was 17 months as of Oct. 26. The company reported no serious treatment-related side effects (grade 3 or worse) and no patients stopping treatment because of side effects.8-K
TD Cowen analyst Tyler Van Buren called the risk reduction "exceptional." It beat the 30% to 40% reduction that management and investors had been hoping the drug would surpass, he wrote, BioPharma Dive reported.BioPharma Dive
The release gave that relative figure, not how many patients in each group stayed free of cancer. OncoDaily noted that absolute recurrence-free survival rates, the median and detailed subgroup results "were not included in the initial release." It also wrote that the results do not show whether the drug is better than other treatments placed in the bladder, since the comparison was surveillance.OncoDaily
RBC Capital Markets analyst Leonid Timashev said the data "clears even the most optimistic bars," BioPharma Dive reported. He cautioned that the full dataset will be critical to "better understand" how the drug performed.BioPharma Dive The company will present it on Dec. 2.8-K
Two executives buy shares
Kuan's purchase was about 30,000 shares. It lifted his direct holding about 15%, to about 228,900 shares. The filing was accepted at 4:30 p.m. on Nov. 18.Form 4
Before this, his filings show stock option grants and two option exercises in March, in which the company kept some of the shares toward the exercise price. None shows a purchase.EDGAR
Isabel Kalofonos, chief commercial officer since October, bought 3,751 shares at $79.755 the same day through a family trust she is a trustee of, about $299,000.Form 4 Her Form 3, covering Oct. 13, when she became an officer, listed no shares.Form 3 Neither filing says why they bought.
How the first application's date moved
The first application is for a different group: patients with high-risk cancer that no longer responds to BCG, the standard bladder treatment. The company puts that group at up to 25,000 patients. Its case rests on another Phase 3 trial, BOND-003, in which 75.5% of patients in its group with CIS, a flat form of the cancer, had a complete response at some point, the company says.10-Q
The company files that application in pieces, a "rolling" submission the FDA allows for drugs with fast track or breakthrough therapy designation. Cretostimogene has both.FDA10-Q In August 2025, CG Oncology said it would start in the fourth quarter. It did, and on Nov. 14, 2025, it said it expected to complete the submission in 2026.8-K10-Q8-K
On May 8, "following alignment discussions with FDA," it set the fourth quarter of 2026. It repeated that on Aug. 6 and again on Nov. 6.8-K8-K8-K
This trial served as the basis for our Biologics License Application (BLA) submission for our initial indication to the U.S. Food and Drug Administration (FDA), which we expect to complete in the fourth quarter of 2026.
On Nov. 16, Kuan said the FDA's feedback led the company to widen the first application. It had been for patients with CIS, with or without papillary tumors. It will now also include patients with high-grade papillary tumors only. "To incorporate the additional data, we now expect to complete the submission before the end of March 2027," he said.8-K Writing about that first application, BioPharma Dive said the company has "pushed back the timelines for that submission multiple times."BioPharma Dive
The company said all the manufacturing work needed for both applications is done. It expects to file the second, based on PIVOT-006, in the second quarter of 2027.8-K
The company had $984.5 million of cash and marketable securities on Sept. 30. It said Nov. 6 that this is enough to fund operations through 2029. It lost $196.1 million in the first nine months of the year.8-K10-Q
The trial readout moved too. On Jan. 9, the company moved it up to the first half of 2026, "nearly one year ahead of schedule." It said enrollment had finished early.8-K It still said the first half on May 8. On Aug. 6 it said "the near-term." On Nov. 6 it said November, and on Nov. 16 the results came out.8-K8-K8-K
The Nov. 16 release does not say how the FDA gave its feedback, or what the feedback said beyond leading to the added patients.8-K
Also in the filings
Director Leonard Post exercised options on 1,000 shares at $0.60 and sold them at $92.00 on Nov. 16, his Form 4 shows. He sold under a trading plan adopted March 5, 2026.Form 4
What to watch
The full PIVOT-006 data at the Society of Urologic Oncology's annual meeting.
12-month data from two other cretostimogene studies, BOND-003 Cohort P and CORE-008 Cohort CX, the company said Nov. 6.
The first application, for BCG-unresponsive patients, is due to be complete.
The second application, based on PIVOT-006.
The paper trail
CG Oncology's own dates for the first FDA application and the PIVOT-006 readout, Aug. 8, 2025 through Nov. 18, 2026, with the time EDGAR accepted each filing (Eastern).
| Filed (ET) | Form | Filer | What it shows |
|---|---|---|---|
| Aug. 8, 2025, 8:15 a.m. | 8-K | CG Oncology | Application to start in the fourth quarter of 2025. |
| Nov. 14, 2025, 8:15 a.m. | 8-K | CG Oncology | Rolling application started; complete submission expected in 2026. |
| Jan. 9, 2026, 8:45 a.m. | 8-K | CG Oncology | PIVOT-006 readout moved to the first half of 2026, "nearly one year ahead of schedule." |
| May 8, 2026, 8:45 a.m. | 8-K | CG Oncology | Application completion expected in the fourth quarter of 2026, after talks with the FDA. Readout in the first half. |
| Aug. 6, 2026, 8:30 a.m. | 8-K | CG Oncology | Readout "anticipated in the near-term." Application still in the fourth quarter. |
| Nov. 6, 2026, 8:30 a.m. | 8-K | CG Oncology | Readout in November. Application in the fourth quarter. |
| Nov. 6, 2026 | 10-Q | CG Oncology | "Which we expect to complete in the fourth quarter of 2026." |
| Nov. 16, 2026, 8:15 a.m. | 8-K | CG Oncology | PIVOT-006 results. First application now due before the end of March 2027; second in Q2 2027. |
| Nov. 18, 2026, 4:30 p.m. | 4 | Arthur Kuan | Bought 30,000.32 shares at $78.88. |
| Nov. 18, 2026, 4:30 p.m. | 4 | Isabel Kalofonos | Bought 3,751 shares at $79.755 through a family trust. |
Sources
20 sources, 14 of them public records
Public records
- CG Oncology, Form 8-K, Exhibit 99.1: PIVOT-006 Phase 3 topline resultsSEC EDGAR · Nov. 16, 2026
- CG Oncology, Form 8-K (Items 7.01 and 8.01)SEC EDGAR · Nov. 16, 2026
- CG Oncology, Form 10-Q for the quarter ended Sept. 30, 2026SEC EDGAR · Nov. 6, 2026
- CG Oncology, Form 8-K, Exhibit 99.1: third quarter 2026 resultsSEC EDGAR · Nov. 6, 2026
- CG Oncology, Form 8-K, Exhibit 99.1: second quarter 2026 resultsSEC EDGAR · Aug. 6, 2026
- CG Oncology, Form 8-K, Exhibit 99.1: first quarter 2026 resultsSEC EDGAR · May 8, 2026
- CG Oncology, Form 8-K, Exhibit 99.1: updated timeline for PIVOT-006 topline dataSEC EDGAR · Jan. 9, 2026
- CG Oncology, Form 8-K, Exhibit 99.1: third quarter 2025 resultsSEC EDGAR · Nov. 14, 2025
- CG Oncology, Form 10-Q for the quarter ended Sept. 30, 2025SEC EDGAR · Nov. 14, 2025
- CG Oncology, Form 8-K, Exhibit 99.1: second quarter 2025 resultsSEC EDGAR · Aug. 8, 2025
- Form 4, Arthur KuanSEC EDGAR · Nov. 18, 2026
- Form 4, Isabel KalofonosSEC EDGAR · Nov. 18, 2026
- Form 3, Isabel KalofonosSEC EDGAR · Oct. 19, 2026
- Form 4, Leonard E. PostSEC EDGAR · Nov. 17, 2026
Rules and references
- Arthur Kuan's filings: a Form 3 and six Form 4s, January 2024 to November 2026SEC EDGAR · through Nov. 18, 2026
- Guidance for Industry: Expedited Programs for Serious Conditions, Drugs and Biologics (Appendix 2: rolling review)U.S. Food and Drug Administration · May 2014
Reporting
- "CG Oncology drug delivers 'exceptional' results in key bladder cancer trial"BioPharma Dive · Nov. 16, 2026
- "Cretostimogene Reduces Bladder Cancer Recurrence Risk by 68% in Phase 3 PIVOT-006 Trial"OncoDaily · Nov. 17, 2026
Data
- End-of-day prices for CGON, and for SPY and QQQ on the chart (Tiingo)KeyVex · through Nov. 19, 2026
- Insider transactions for CGONKeyVex · through Nov. 19, 2026
How we got these numbers
- Prices are end-of-day closes as traded. Daily moves are close to close. KeyVex did not yet have the Nov. 20 close when this story was written, so the chart ends at the Nov. 19 close. "Highest close since it listed" covers every close from CG Oncology's first trading day, Jan. 25, 2024. The Nasdaq 100 and S&P 500 lines follow QQQ and SPY, rebased to CG Oncology's close at the start of the range shown. The Filings switch shows the markers from KeyVex's CG Oncology page: some insider trades, Form 144 notices and 8-Ks. They are not every filing, and not all are tied to this story.
- Kuan's purchase is 30,000.32 shares at $78.88, or $2,366,425, as his Form 4 reports it; his direct holding went from 198,916 shares to 228,916.32. Kalofonos's is 3,751 shares at $79.755, or $299,161.
- "No earlier purchase" covers Kuan's Form 3 and all six of his Form 4s on EDGAR, filed Jan. 24, 2024 through Nov. 18, 2026.
- The 68% figure is the company's description of a hazard ratio of 0.32 (95% confidence interval 0.23 to 0.45), a relative measure. The company has not yet published how many patients in each group had their cancer return.
- The patient counts are the company's own: about 50,000 intermediate-risk and high-grade Ta patients with no approved treatment after surgery (its Nov. 16 release), and up to 25,000 addressable BCG-unresponsive patients in the U.S. (its 10-Q).




